Related Experiment Video
Updated: Apr 19, 2026

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2
Gang Wang1, Yubei Sun, Yifu He
11 Department of Oncology, Jinan Central Hospital, Shandong University , Jinan, People's Republic of China .
Backgrounds:
Interferon (IFN)-α has been used to treat hepatocellular carcinoma (HCC). Here, we report that the IFN-α-induced microRNA-26a (miR-26a) can inhibit HCC proliferation and invasion by suppressing enhancer of zeste homologue 2 (EZH2) expression in tumor cells.
Materials And Methods:
First, the miR-26a transcription level was quantified by real-time quantitative PCR in the HCC specimens from IFN-α-treated HCC patients. Next, we transfected HepG2 cells with miR-26a mimics and miR control, and then we investigated the influence of miR-26a mimic transfection on HepG2 cell proliferation and invasion.
Results:
It was shown that there was increased miR-26a accompanied with downregulated EZH2 expression in the HCC specimens, and EZH2 mRNA levels were inversely correlated with miR-26a expression. There was a dose-response correlation between the IFN-α dosage and EZH2 expression. In addition, the miR-26a mimic transfection decreased the EZH2 expression level significantly in the transfected HepG2 cells and inhibited HepG2 cell proliferation and invasion effectively.
Conclusion:
Our results indicate that miR-26a exerts growth inhibition in HCC and that its inhibitory effect is mediated briefly by blocking EZH2 expression.
Insights
Interferon-alfa (IFN-α) treatment increases microRNA-26a (miR-26a) in liver cancer. This miR-26a inhibits tumor growth and spread by reducing enhancer of zeste homologue 2 (EZH2) expression.
Area of Science:
- Oncology
- Molecular Biology
- Hepatocellular Carcinoma Research
Background:
- Interferon-alfa (IFN-α) is a therapeutic agent for hepatocellular carcinoma (HCC).
- MicroRNAs play crucial roles in cancer development and progression.
- The specific role of miR-26a in IFN-α-treated HCC warrants further investigation.
Purpose of the Study:
- To investigate the role of microRNA-26a (miR-26a) in hepatocellular carcinoma (HCC).
- To determine the mechanism by which miR-26a affects HCC proliferation and invasion.
- To explore the relationship between miR-26a, enhancer of zeste homologue 2 (EZH2), and IFN-α treatment in HCC.
Main Methods:
- Quantification of miR-26a transcription levels in HCC specimens using real-time quantitative PCR.
- Transfection of HepG2 cells with miR-26a mimics to assess its functional impact.
- Evaluation of cell proliferation and invasion following miR-26a mimic transfection.
Main Results:
- Increased miR-26a expression was observed in HCC specimens, inversely correlated with EZH2 expression.
- IFN-α dosage showed a dose-response correlation with EZH2 expression levels.
- miR-26a mimic transfection significantly reduced EZH2 expression and inhibited HepG2 cell proliferation and invasion.
Conclusions:
- miR-26a demonstrates significant growth inhibitory effects in HCC.
- The anti-cancer activity of miR-26a in HCC is mediated through the suppression of EZH2 expression.
- These findings highlight miR-26a as a potential therapeutic target in HCC treatment.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
Inhibitors of Viral Protein Synthesis
Abnormal Proliferation

